TLDRocket
Sign in

Drug Discovery Has No Magic Wands

a16z

Opinion — commentary, not a factual news event.

Daphne Koller argues that AI's promise to cure disease through superintelligence overlooks a critical bottleneck: we lack sufficient understanding of human biology to identify which disease mechanisms are worth targeting. While AI has excelled at molecular design (stage 2 of drug discovery), over 90% of drugs fail in clinical trials because researchers target the wrong biological mechanisms, not because molecules are poorly designed. Real progress requires massive new biological measurement efforts and human clinical data, which no amount of computational optimization can replace, making the current industry focus on better molecular design tools largely misguided.

Why it matters

AI will not be a magic wand for drug discovery since we don't understand human biology well enough for AI to find hidden cures. The path to real cures is to measure biology in the right way and use AI to derive novel insights from those measurements.

Related stories

The daily briefing

Every AI story that matters, in your inbox by 8am.

TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.